Recombinant human erythropoietin in the treatment of chemotherapy- induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study

C. Oberhoff, B. Neri, D. Amadori, K. U. Petry, T. Gamucci, U. Rebmann, M. R. Nowrousian, R. Voigtmann, S. Monfardini, J. P. Armand, R. Herrmann, J. Netter-Pinon, N. Tubiana-Mathieu, H. Zwierzina

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Anemia is a common side effect of anticancer chemotherapy. Blood transfusion, previously the only available treatment for chemotherapy- induced anemia, may result in some clinical or subclinical adverse effects in the recipients. Recombinant human erythropoietin (rhEPO) provides a new treatment modality for chemotherapy-induced anemia. Patients and methods: To evaluate the effect of rhEPO on the need for blood transfusions and on hemoglobin (Hb) concentrations, 227 patients with solid tumors and chemotherapy-induced anemia were enrolled in a randomized, controlled, clinical trial. Of 189 patients evaluable for efficacy, 101 received 5000 IU rhEPO daily s.c., while 88 patients received no treatment during the 12-week controlled phase of the study. Results: The results demonstrate a statistically significant reduction in the need for blood transfusions (28% vs. 42%, P = 0.028) and in the mean volume of packed red blood cells transfused (152 ml vs. 190 ml, P = 0.044) in patients treated with rhEPO compared to untreated controls. This effect was even more pronounced in patients receiving platinum-based chemotherapy (26% vs. 45%, P = 0.038). During the controlled treatment phase, the median Hb values increased in the rhEPO patients while remaining unchanged in the control group. The response was seen in all tumor types. Conclusions: RhEPO administration at a dose of 5000 IU daily s.c. increases hemoglobin levels and reduces transfusion requirements in chemotherapy-induced anemia, especially during platinum- based chemotherapy.

Original languageEnglish
Pages (from-to)255-260
Number of pages6
JournalAnnals of Oncology
Volume9
Issue number3
DOIs
Publication statusPublished - Mar 1998

Keywords

  • Anemia
  • Chemotherapy
  • Malignancy
  • Recombinant human erythropoietin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology

Fingerprint

Dive into the research topics of 'Recombinant human erythropoietin in the treatment of chemotherapy- induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study'. Together they form a unique fingerprint.

Cite this